Ophthalmology Prior Auth: Cataract Surgery and Injections

Prior Authorization in High-Volume Ophthalmology

Ophthalmology practices operating at 40–80 patients per day generate a correspondingly high volume of prior authorization requests — cataract surgery for every surgical patient, anti-VEGF injection authorizations for hundreds of retina patients, blepharoplasty and ptosis repair cases, and an increasing volume of requests for newer ophthalmic drugs (faricimab, brolucizumab). Managing this volume efficiently is an operational prerequisite for high-volume ophthalmology.

The authorization landscape in ophthalmology is shaped by several characteristics unique to the specialty:

High procedure volume per patient: A retina patient receiving monthly bevacizumab or quarterly aflibercept may require 12+ injection visits per year, each potentially requiring authorization or at minimum being tracked against an annual authorization. Renewal management — ensuring authorizations don't lapse mid-treatment — is as important as initial authorization.

Visual acuity-based criteria: Unlike most specialties where prior auth criteria are based on diagnosis and prior treatment, ophthalmology authorizations for cataract surgery and some other procedures use objective visual acuity measurements as the primary criterion. Understanding the specific VA thresholds for each payer is prerequisite knowledge for authorization staff.

Premium vs. standard implant splits: Cataract surgery with premium IOLs (toric, multifocal, extended depth-of-focus) is covered partially — the standard IOL and surgery are authorized, while the premium IOL upgrade is patient financial responsibility ($1,500–3,500 per eye). Ensuring patients understand and sign for the financial split before surgery is both a revenue protection and a compliance requirement.

This guide covers the major ophthalmology prior authorization categories — cataract surgery, anti-VEGF injections, and eyelid procedures — with procedure-specific criteria and documentation strategies.

Cataract Surgery: Visual Acuity Threshold Documentation

Cataract surgery (CPT 66984 — extracapsular cataract extraction with IOL implant, CPT 66982 — complex cataract) prior authorization requires documentation of visual acuity impairment that meets or exceeds the payer's threshold and functional impairment from that visual acuity loss.

VA threshold requirements by payer type: - Medicare (traditional): Does not require prior authorization for cataract surgery — it is a covered benefit when the surgeon documents that the lens opacity is impairing vision and function. However, Medicare Advantage plans DO require prior auth and have varying VA thresholds. - Medicare Advantage: Most plans require best corrected visual acuity (BCVA) of 20/40 or worse in the operative eye, OR BCVA of 20/30 to 20/40 with documented functional impairment (night driving difficulty, glare disability on standardized glare testing, difficulty with activities of daily living). Some MA plans apply a 20/50 or 20/60 threshold. - Commercial payers: Similar to MA — BCVA ≤20/40 is the most common threshold, with functional impairment documentation required when VA is better than 20/40. - Medicaid: Varies significantly by state. Some state Medicaid programs require 20/60 or 20/80 threshold; others follow Medicare criteria.

VA documentation requirements: The authorization must include the date of the VA measurement, the corrected acuity (with current glasses or contact lenses), and the acuity in each eye separately. VA must be measured by qualified staff using calibrated charts at the appropriate test distance (20 feet or 6 meters for Snellen, 4 meters for ETDRS). Technician-documented VA from the pre-testing workflow should be used — not physician-estimated VA.

BCVA better than 20/40: Many patients who are functionally significantly impaired by their cataract have BCVA of 20/25–20/40 — still relatively preserved on the Snellen chart. For these patients, authorization requires functional impairment documentation: - Contrast sensitivity testing (Pelli-Robson or Mars contrast sensitivity chart) — reduced contrast sensitivity is documented even when Snellen VA is preserved - Glare testing (BAT — brightness acuity tester) — severe glare disability with cataract confirmed - Patient self-report of visual difficulty (ADL questionnaire — VFQ-25 or NVFQ) - Physician documentation of the specific functional limitation (unable to drive safely, difficulty reading, occupational impact)

Premium IOL: Separating Covered and Non-Covered Components

Premium IOLs — toric (astigmatism-correcting), multifocal, extended depth-of-focus (EDOF), and light-adjustable lenses — are not covered by Medicare or most commercial payers for the additional cost beyond a standard monofocal IOL. Understanding this financial structure — and communicating it clearly to patients before surgery — is both a billing compliance requirement and a patient satisfaction issue.

Coverage structure for cataract surgery with premium IOL: - Covered by insurance: Cataract surgery facility fee, surgeon fee (CPT 66984 or 66982), anesthesia, standard monofocal IOL (included in the surgery fee under current CMS bundling) - Patient financial responsibility: The cost difference between the premium IOL and a standard IOL, plus any additional professional service (e.g., IOL power calculation using premium technologies such as the ORA system intraoperatively, or laser-assisted cataract surgery/LACS) - Not separately billable to Medicare: The premium lens upgrade itself, laser fragmentation (femtosecond laser-assisted cataract surgery), and limbal relaxing incisions (LRI) for astigmatism correction

Advanced billing requirements: CMS mandates that practices provide patients with a written notice of non-covered services (ABN — Advance Beneficiary Notice) before performing any non-covered service in conjunction with a covered service. For premium IOL cataract surgery, the ABN (or practice's equivalent financial responsibility agreement) must specify the exact amount the patient will be charged for the premium components. This document must be signed before surgery.

Toric IOL authorization considerations: For patients with significant corneal astigmatism (≥0.75 D) who choose a toric IOL, the toric lens calculation using corneal topography (Pentacam, Atlas) and premium biometry formulas (Barrett Toric, Kane Toric) is part of the surgical planning — not a separately billable diagnostic service. However, ORA (optiwave refractive analysis) intraoperative aberrometry — used to confirm or refine IOL power and toric axis during surgery — is a patient-pay service billed at $200–400 per eye, not reimbursed by insurers.

Documentation for combined coverage/non-coverage: The operative report and billing records must clearly distinguish the covered components (cataract extraction, standard IOL baseline) from the non-covered premium components. Mixed documentation that blurs this distinction creates audit risk under the False Claims Act.

Anti-VEGF Injections: Wet AMD, DME, and RVO Authorization

Anti-VEGF intravitreal injection prior authorization covers three major diagnoses — wet age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema from retinal vein occlusion (RVO) — each with distinct payer criteria.

Wet AMD (neovascular AMD) authorization (ICD-10: H35.31-H35.32): - Fluorescein angiography (FA) confirming choroidal neovascularization (CNV): FA documentation (ideally the actual FA report and images) should be included with the initial authorization. Most payers require FA within the past 6–12 months for new authorizations. - OCT confirming subretinal fluid, intraretinal fluid, or pigment epithelial detachment consistent with active nAMD - VA documentation: Most payers authorize anti-VEGF for VA from 20/32 to approximately 20/800 — very poor VA (hand motion or worse) may be considered "end-stage" and not covered by some plans - Initial authorization: typically 12 months, unlimited injections (consistent with PRN or treat-and-extend protocols). Some payers authorize 6 months initially; renewal is usually straightforward with OCT demonstrating treatment response.

DME authorization (ICD-10: E10.3xx, E11.3xx): - OCT confirming center-involved DME (central subfield thickness ≥250–300 μm on SD-OCT depending on machine and payer criteria) - Diabetes documentation (Type 1 or Type 2, HbA1c if available) - Best corrected VA documentation - For some payers: prior laser photocoagulation trial (focal/grid laser) for non-center-involved DME — though anti-VEGF is now first-line per AAO guidelines for center-involved DME with VA impairment, many older payer policies still reference laser - HbA1c level: If HbA1c >10%, some payers require documentation of medical management discussion before authorizing anti-VEGF, arguing that improving glycemic control may resolve DME

RVO authorization (ICD-10: H34.81xx — BRVO; H34.23 — CRVO): - Documentation of RVO diagnosis: fundus photograph, FA, or OCT showing venous occlusion pattern - Macular edema confirmed by OCT (center-involved) - Most payers: no step therapy required — anti-VEGF is covered as first-line treatment for RVO-associated macular edema

Anti-VEGF Drug Selection and Authorization: Initial vs. Renewal

Anti-VEGF drug choice — bevacizumab, ranibizumab, aflibercept, faricimab, or brolucizumab — affects both the prior authorization process and the practice's revenue per injection. Understanding payer formulary positioning for each agent is prerequisite knowledge for retina practice authorization staff.

Bevacizumab (Avastin — off-label for ophthalmic use): Not FDA-approved for ophthalmic indications, but widely used based on clinical trial equivalence data (CATT trial, IVAN trial). Compounded bevacizumab from 503B pharmacies is not subject to the same payer authorization processes as FDA-approved drugs — most payers cover bevacizumab injections without prior authorization for retinal indications, or with a simple notification. Drug cost: $50–70 per 1.25 mg dose from compounding pharmacy. Not reimbursed separately under Medicare Part B — only the administration code (67028) is billed to Medicare for bevacizumab.

Aflibercept (Eylea — 2 mg and 8 mg): FDA-approved for nAMD, DME, RVO. Medicare Part B covers aflibercept under buy-and-bill: J-code J0178, billed at ASP + 6% (~$900–1,100 per 2 mg dose). Most commercial payers authorize aflibercept after bevacizumab "failure" (defined as persistent fluid on OCT after 3 bevacizumab injections) or as first-line if medical criteria support. Aflibercept 8 mg (Eylea HD) was approved in 2023 — payer coverage policies for the high-dose formulation are still evolving; many plans require separate authorization and some restrict it to specific indications.

Faricimab (Vabysmo): Bispecific antibody targeting both VEGF-A and Ang-2; FDA-approved for nAMD and DME. Advantage over aflibercept: treat-and-extend intervals up to 16 weeks achieved in 45%+ of patients. Payer positioning: most plans require bevacizumab or aflibercept failure before faricimab authorization. J-code J1741 — ASP + 6% for Medicare (~$1,100–1,400 per dose). Authorization for faricimab should document prior anti-VEGF history and the clinical rationale for extended-interval dosing.

Renewal authorization strategy: For established anti-VEGF patients, renewal every 12 months should include: most recent OCT demonstrating treatment response (fluid reduction), current VA compared to pre-treatment baseline, treatment frequency in the prior authorization period, and physician attestation that continued treatment is necessary. Practices that submit renewal auths with minimal documentation have the highest renewal denial rates — a complete renewal package mirrors the initial auth in clinical detail.

Blepharoplasty: Visual Field Obstruction Documentation

Blepharoplasty — surgical removal of excess eyelid skin and/or fat — is the most commonly performed eyelid procedure in ophthalmology and oculoplastics, and the most commonly disputed prior authorization in the specialty. Payers cover functional blepharoplasty (medically necessary — excess skin obstructing superior visual field) but not cosmetic blepharoplasty (performed for appearance without functional impact). Distinguishing and documenting the functional vs. cosmetic determination is the central prior auth challenge.

Upper eyelid blepharoplasty authorization criteria (CPT 15822–15823): 1. Marginal reflex distance (MRD1): Distance from the corneal light reflex to the upper eyelid margin. Normal MRD1 is 3.5–5 mm. MRD1 ≤2 mm documents significant ptosis contributing to visual field obstruction. 2. Visual field testing: Humphrey visual field testing with and without tape lifting the ptotic skin from the visual axis is the gold standard documentation. Most payers require: VF showing superior field loss of ≥12° of superior visual field, OR ≥30% improvement in VF with tape lifting. The taped VF should be included in the authorization along with the baseline (non-taped) VF. 3. Photography: Standardized photographs showing the eyelid in primary gaze — the ptotic tissue should be visibly encroaching on the visual axis. 4. Physician documentation: The clinical note should explicitly state: eyelid margin-to-reflex distance, visual field findings with quantified field loss, functional symptoms (brow fatigue from compensatory frontalis overaction, reading difficulty, driving difficulty from superior field loss), and the clinical determination that surgery is functionally indicated.

Lower eyelid blepharoplasty: Lower lid blepharoplasty is rarely covered by insurance — it does not typically obstruct visual fields and is considered cosmetic in most circumstances. Exceptions: ectropion repair (CPT 67914–67917), entropion repair (CPT 67921–67924), and retraction repair are functional/reconstructive procedures that are insured.

Ptosis repair (levator resection, frontalis suspension) is separately authorized from blepharoplasty and has different criteria — focusing on levator function measurement and MRD1 rather than visual field obstruction.

Pterygium, Glaucoma, and Other Ophthalmology Authorization

Beyond cataract, anti-VEGF, and eyelid procedures, ophthalmology practices encounter prior authorization requirements for several other common procedures.

Pterygium excision (CPT 65420 — pterygium excision without graft; CPT 65426 — with graft): Most payers cover pterygium excision when: the pterygium crosses onto the cornea (documented with slit lamp measurement of encroachment in mm past the limbus), induces significant irregular astigmatism (topography documentation), reduces BCVA, or threatens the visual axis. Asymtomatic, non-progressive pterygium is considered cosmetic. The authorization should include: corneal topography showing pterygium-induced irregular astigmatism, slit lamp photograph with limbus-to-pterygium distance documented, and VA documentation.

Glaucoma surgery (trabeculectomy CPT 66170/66172, MIGS procedures, tube shunt) authorization requires: elevated IOP documentation despite maximum tolerated medical therapy (list all glaucoma drops with duration of use — typically timolol, brimonidine, dorzolamide, latanoprost or bimatoprost, with IOP values recorded while on maximal therapy), progressive VF loss or progressive optic nerve cupping on serial OCT/VF testing, and for MIGS procedures (iStent, Hydrus, OMNI, KDB), documentation that surgery is being performed concurrently with cataract surgery (most MIGS procedures are authorized only in combination with cataract extraction).

Intracanalicular drug delivery devices (Dextenza — dexamethasone 0.4 mg insert, CPT 68841 + J1097): Prior auth required from most commercial payers and some Medicare Advantage plans. Criteria: documented inflammation or pain following cataract surgery or pterygium surgery.

Corneal cross-linking (CXL) for keratoconus (CPT 0402T): Prior auth requirements include: corneal topography confirming keratoconus (KC grade, Kmax >47 D), documented progression over 12 months (>1 D Kmax increase, corneal thinning), and BCVA documentation. Medicare does not cover CXL under traditional Medicare (the CPT is a Category III code); Medicare Advantage coverage varies by plan.

Building an Efficient Ophthalmology Prior Auth Program

Given the volume and complexity of ophthalmology prior authorizations — high-volume cataract pre-auths, monthly anti-VEGF injection tracking, and scattered eyelid/glaucoma/cornea auths — systematic program design is essential for keeping up without excessive staffing cost.

Staffing model: A 3-physician ophthalmology practice with active retina services typically needs 1.5–2 FTE dedicated prior auth staff — one person handling retina injection renewals (monthly management of ongoing authorizations) and one handling surgical and new specialty authorizations. Combining all auth work into the billing/front desk team without dedicated focus leads to authorization lapses and treatment delays.

Technology integration: Electronic prior auth (ePA) integration with the EHR is particularly valuable in ophthalmology because of the repetitive nature of anti-VEGF injection authorizations. ePA platforms that allow batch submission of monthly injection authorizations — rather than individual form completion per patient — dramatically reduce staff time. CMS ePA mandates for Medicare Advantage (effective 2027) are accelerating payer ePA adoption.

Anti-VEGF auth tracking system: The practice needs a database or EHR-integrated tracker showing: each anti-VEGF patient's current authorization number, authorization expiration date, payer, and drug. The tracker should generate alerts 60 days before authorization expiration to allow adequate renewal lead time. Some payers process renewal auths in 5–7 business days; others take 3–4 weeks — lead time calibration by payer prevents authorizations from lapsing between appointment days.

Payer-specific criteria library: Ophthalmology practices should maintain an updated library of payer-specific coverage criteria for cataract surgery, anti-VEGF agents, and eyelid procedures for their top 10 payers by patient volume. Criteria change annually with payer formulary updates — the criteria library should be reviewed every January and updated from payer LCD/NCD publications and commercial policy bulletins. Having this reference available to auth staff at the point of submission prevents the back-and-forth of incomplete submissions and information requests.